The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.
 
Naoko Matsuda
No Relationships to Disclose
 
Xiaoping Wang
No Relationships to Disclose
 
Savitri Krishnamurthy
No Relationships to Disclose
 
Ricardo H. Alvarez
Employment - Cancer Treament Centers of America
 
Jie S. Willey
No Relationships to Disclose
 
Bora Lim
No Relationships to Disclose
 
Charla A. Parker
No Relationships to Disclose
 
Gildy Babiera
No Relationships to Disclose
 
Daniel J. Booser
Stock and Other Ownership Interests - Johnson & Johnson
 
James L. Murray
No Relationships to Disclose
 
Banu Arun
Consulting or Advisory Role - Abbvie
Research Funding - Avon Foundation; Susan G. Komen for the Cure
 
Abenaa M. Brewster
No Relationships to Disclose
 
James M. Reuben
Consulting or Advisory Role - Angle
 
Michael Charles Stauder
Consulting or Advisory Role - MD Anderson Cancer Center
 
Wendy A. Woodward
No Relationships to Disclose
 
Anthony Lucci
No Relationships to Disclose
 
Sarah Marie DeSnyder
No Relationships to Disclose
 
Debu Tripathy
Consulting or Advisory Role - Merck; Nektar; Novartis; Oncoplex Diagnostics; Pfizer
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Merck; Novartis
 
Vicente Valero
No Relationships to Disclose
 
Naoto T. Ueno
Research Funding - Amgen (Inst); Celgene (Inst)